[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognition-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognition-disorder":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,80,108,134,167,205,239,271,305],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":56,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100454745","interventions-in-mathematics-and-cognitive-skills-100454745",false,"NCT05201534","Interventions in Mathematics and Cognitive Skills","Interventions in Math Learning Disabilities: Cognitive and Neural Correlates","Inclusion Criteria:\n\n1. Elementary school aged children starting from first grade (6-12 years old)\n2. IQ: Participants with a Full Scale IQ \\> 70 on the Wechsler Abbreviated Scle of Intelligence (WASI-II).\n3. Identification of Mathematical Learning Disabilities: Scores below the 35th percentile percentile on symbolic number processing test in Numeracy Screener and two or more Wechsler Individual Achievement Test (WIAT-IV) math subtests\n4. Identification of typically developing children: Scores at or above the 35th percentile percentile on symbolic number processing test in Numeracy Screener and all WIAT-IV math subtests\n5. Normal or corrected-to-normal vision and no hearing impairments\n6. Inclusion in MRI scan session: Right-handed\n\nExclusion Criteria:\n\n1. History of neurological or psychiatric disorder (i.e., schizophrenia, psychosis, depression, or attention deficit hyperactivity disorder.)\n2. History of trauma involving head injury\n3. Consistent psychiatric medications\n4. Exclusion from MRI scan session: No major contraindication for magnetic resonance imaging (MRI) - braces, metal implants, pacemakers, vascular stents, metallic ear tubes, consistent exposure to metal, claustrophobia)",true,"ALL","6 Years","12 Years",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to investigate neurocognitive mechanisms underlying response to intervention aimed at enhancing, and remediating weaknesses in, numerical skills in children, including those with mathematical learning disabilities (MLD).",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55],"Math Learning Disability","Child Development","Developmental Disability","Learning Disabilities","Learning Disabled","Learning Curve","Mathematics Disorder","Dyscalculia","Dyscalculia, Primary","Dyscalculia, Acquired","Specific Learning Disorder, With Impairment in Mathematics","Individuality","Behavior, Child","Behavior and Behavior Mechanisms","Behavior","Decision Making","Neuronal Plasticity","Cognition","Cognition Disorder","Cognitive Dysfunction","Cognitive Change","Cognitive Impairment, Mild","Cognitive Developmental Delay","Cognitive Orientation","Cognitive Delay, Mild","Cognitive Deficits, Mild","Cognitive Abnormality","Neuroscience",[57,58,59,60,61,62,63,64,65,66],"Numerical skills in children","Low math abilities","Mathematical Learning Disabilities","Mathematical Concepts","Mathematics","Transfer, Psychology","Generalization, Psychology","Early Intervention, Educational","Neural Pathways","Neural Networks, Computer","RECRUITING","2026-06-22",{"date":70,"type":71},"2026-06-25","ACTUAL",{"date":73,"type":71},"2023-05-05",{"date":75,"type":22},"2026-08-31",{"name":77,"class":78},"Stanford University","OTHER",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100636967","repair-sleep-study-100636967","NCT07572565","REPAIR Sleep Study","Testing Cognitive Behavioral Therapy for Insomnia (CBT-I) on Dyadic Sleep in Dementia: A Randomized Control Trial","Inclusion Criteria:\n\nPLwCC and Caregiver\n\n* Have Insomnia Severity Index (ISI) ≥10\n* Have difficulty initiating or maintaining sleep or waking up too early at least three nights per week\n* Have sleep disturbances persisting for at least three months\n* Have daytime impairment (e.g., fatigue, mood disturbance)\n* Community-dwelling\n* Co-residing with each other\n* Have internet access\n* No history of surgery in the past 4 weeks\n\nCaregivers -Regularly assist the care recipient with ≥1 of 7 basic activities of daily living61 or ≥1 of 7 Instrumental Activities of Daily Living for the past 6 months.\n\nPLwD\n\n-Reported or diagnosed cognitive impairment; able to complete simple directives.\n\nExclusion Criteria:\n\nPLwCC or Caregiver:\n\n* A diagnosis of psychosis, major depressive disorder, or bipolar disorder that is not currently treated;\n* Having had substance or alcohol dependency, or active suicidality in the past year\n* Currently have narcolepsy or restless leg syndrome\n* Does shift work\n* Plan trans-meridian travel during the period of data collection blocks\n* Hearing or visual impairment\n\nCaregivers\n\n* Dementia or cognitive impairment.\n* Individuals who are not yet adults\n* Pregnant women\n* Prisoners\n* Individuals who are not able to clearly understand English.","18 Years",{"count":89,"type":22},120,[25],"The goal of this study is to learn whether a videoconference-delivered CBT-I program (REPAIR Sleep) can improve sleep and psychological well-being in caregiver-PLwD dyads. The main questions it aims to answer are:\n\n* Does REPAIR Sleep improve insomnia severity and other sleep outcomes?\n* Does REPAIR Sleep improve psychological outcomes such as mood, stress, and quality of life? Researchers will compare REPAIR Sleep with Healthy Living to see whether REPAIR Sleep leads to greater improvements.\n\nParticipants will:\n\n* Attend five weekly virtual sessions\n* Complete sleep diaries and questionnaires\n* Wear an actigraphy device\n* Complete follow-up assessments over 9 months",[46,93],"Alzheimer Disease",[95,96,97],"Persons living with cognitive changes","Persons living with Alzheimer's disease and related dementias","Cognitive Behavioral Therapy for Insomnia","NOT_YET_RECRUITING","2026-05-01",{"date":101,"type":71},"2026-05-07",{"date":103,"type":22},"2026-07",{"date":105,"type":22},"2028-06",{"name":107,"class":78},"Emory University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":16,"sex":17,"minAge":87,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100624167","meop---multidimensional-evaluations-in-oncological-psychiatry-100624167","NCT07406113","MEOP - Multidimensional Evaluations in Oncological Psychiatry","MEOP","Inclusion Criteria:\n\n* For cases: any subject affected by cancer with a comorbid psychiatric disorder (further defined as \"cases\") or any first-degree relative of a subject of a \"case\" (i.e., i.e. a fist-degree relative of a subject affected by cancer and a psychiatric disorder). These first-degree relatives will be defined as \"cases-rel\".\n* For controls: a) Subjects with cancer who will undergo a consultation in the Clinical and Emergency Psychiatry Unit of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS but who do not show any psychiatric symptoms (further defined as \"oncology-controls\"); b) subjects without cancer who will undergo a psychiatric evaluation in the Clinical and Emergency Psychiatry Unit and present psychiatric symptoms (further defined as \"psy-controls\"); c) Subjects without cancer and with any suspected psychiatric disorder who will undergo a psychiatric evaluation in the Clinical and Emergency Psychiatry Unit and who are not diagnosed with any relevant psychiatric symptoms after the evaluation (further defined as \"healthy controls\"); d) First-degree relatives of \"oncology-controls\", \"psy-controls\" and \"healthy controls\" (further defined as \"control-rel\").\n* Age between 18 and 75 years.\n* Capability of providing written informed consent.\n\nExclusion Criteria:\n\n* Severe cognitive impairment or inability to provide written informed consent.\n* Severe unstable neurological disorders, such as traumatic brain injury, Alzheimer's Disease or dementia.\n* Inability to perform psychiatric or neuropsychological evaluations.","75 Years",{"count":117,"type":22},2000,"OBSERVATIONAL","Cancer is among the leading causes of morbidity and mortality worldwide, profoundly affecting patients' lives at every level, and its psychological and psychiatric impacts remain a major concern. Psychiatric disorders are frequently observed in cancer patients. Nevertheless, they were also underdiagnosed, with a consequent undermining possible interventions. Still, psychiatric disorders in cancer patients are not merely secondary complications but may actively contribute to poor oncological outcomes.\n\nThe pathophysiology of cancer-related psychiatric disorders is multifactorial and is related to several neuropsychological and neurobiological factors. Specifically, the production of cytokines associated with cancer appears to play a role in the development of depression. Tumours trigger an inflammatory response that leads to the release of pro-inflammatory cytokines. These cytokines influence central nervous system function and disrupt the regulation of the HPA axis, contributing to psychological symptoms such as depression, fatigue, sleep disturbances, and appetite loss.\n\nMoreover, psychiatric symptoms in cancer patients are often accompanied by neuropsychological alterations including deficits in memory, executive function, and attention. Compared to other individuals with psychiatric disorders, cancer patients may experience more severe cognitive impairments which can be exacerbated by cancer treatments, including surgery, chemotherapy, and radiotherapy. These treatments stimulate cytokine production by nearby non-cancerous cells and immune cells activated in response to treatment-induced cell death, thereby driving systemic inflammation.\n\nCancer profoundly affects not only patients but also their families, who often bear the emotional and caregiving burden. Being close to a loved one with cancer can lead to significant psychological distress, including anxiety and depression, among family members and caregivers. The ripple effects of this burden underscore the need for a holistic approach to mental health in oncology.\n\nGiven the background presented so far, identifying and managing psychiatric comorbidities in oncological patients and their families is crucial. This multifaceted interplay between cancer and psychiatric disorders necessitates a comprehensive, interdisciplinary approach to understanding, diagnosing, and treating these conditions effectively.",[121,46,122,123,124],"Psychiatric Disorder","Treatment Compliance","Adverse Drug Event","Family Members","2026-02-09",{"date":127,"type":71},"2026-02-12",{"date":129,"type":22},"2026-01-30",{"date":131,"type":22},"2036-01-29",{"name":133,"class":78},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100581676","nutrition-based-interventions-to-prevent-cognitive-decline-100581676","NCT06853405","Nutrition-based Interventions to Prevent Cognitive Decline","NUTRIMIND: Nutrition-based Interventions to Prevent Cognitive Decline","NUTRIMIND","Inclusion Criteria:\n\n* Aged from 55 to 85 years old;\n* At least 4 years in the regular school system;\n* Higher individual risk for dementia defined as a score ≥6 points on the Cardiovascular Risk Factors, Aging and Dementia Dementia Risk Score (CAIDE).\n\nExclusion Criteria:\n\n* Montreal Cognitive Assessment (MoCA) score lower than the validated cutoff points defined as 2 standard deviations below the normative reference value for the corresponding age and education in the Portuguese population;\n* Having a medical condition limiting the participation in the intervention (e.g., blindness, amputation…);\n* Lack of autonomy in daily activities;\n* Diagnosis of dementia or major incapacity.","55 Years","85 Years",{"count":89,"type":22},[25],"This study intends to evaluate the feasibility and the effectiveness of an innovative and integrated nutrition-based intervention addressing key modifiable risk factors for dementia while meeting participants' preferences for nutrition-related sessions. The intervention will include lifestyle group sessions regarding nutrition education and physical activity, individualized cognitive training at home, as well as clinical nutrition consultations.",[47,46,148,149,150],"Memory Disorders","Cognitive Impairment","Neurocognitive Disorders",[152,153,47,154,155,156],"Healthy Aging","Dementia","Diet, Food and Nutrition","Diet, Mediterranean","Randomized Controlled Trial","2025-11-27",{"date":159,"type":71},"2025-12-05",{"date":161,"type":71},"2025-01-27",{"date":163,"type":22},"2026-08",{"name":165,"class":78},"Instituto de Saude Publica da Universidade do Porto",2,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100384702","phase-4-cognitive-outcomes-after-dexmedetomidine-sedation-in-cardiac-surgery-patients-100384702","NCT04289142","Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients","Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients: CODEX Trial","CODEX","Inclusion Criteria:\n\n* Planned CABG (+\u002F- valve, including off-pump) or valve replacement via sternotomy\u002Fthoracotomy, with initial recovery in the Cardiovascular Intensive Care Unit (CVICU)\n* Age ≥60\n\nExclusion Criteria:\n\n* Lack of patient consent\n* Pre-operative major cognitive dysfunction (CogState Brief Battery score \\\u003C 80) at screening\n* Aortic arch replacement\u002Fre-implantation (surgery requiring hypothermic circulatory arrest, e.g. Bentall procedure)\n* Allergy\u002Fcontraindication to dexmedetomidine (untreated 2nd degree type 2 or 3rd degree heart block (pacemaker), cirrhosis, HR \\\u003C 50 , grade 4 LV, renal failure or on renal replacement therapy)\n* Unlikely to comply with study assessments (e.g. no fixed address, cannot complete cognitive tests at the 3, 6, and 12 month time points)","60 Years",{"count":177,"type":22},2400,[179],"PHASE4","Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investigators propose to investigate the role of Dexmedetomidine (DEX) in preventing long-term POCD after cardiac surgery and enhancing early postoperative recovery. It is anticipated that DEX will be the first effective preventative therapy for POCD, improve patient outcomes, and reduce length of stay and healthcare costs.",[182,47,46,150,183,184,185,186,187,188,189,190,191,192,193,194,195],"Delirium","Mental Disorders","Confusion","Neurobehavioral Manifestations","Neurologic Manifestations","Nervous System Diseases","Signs and Symptoms","Dexmedetomidine","Hypnotics and Sedatives","Central Nervous System Depressants","Physiological Effects of Drugs","Analgesics, Non-Narcotic","Analgesics","Molecular Mechanisms of Pharmacological Action",{"date":197,"type":71},"2025-12-01",{"date":199,"type":71},"2019-12-01",{"date":201,"type":22},"2029-03",{"name":203,"class":78},"Sunnybrook Health Sciences Centre",8,{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":142,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":222,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":238},"100536688","depth-of-anesthesia-on-postoperative-delirium-and-cognitive-after-surgery-100536688","NCT06268080","Depth of Anesthesia on Postoperative Delirium and Cognitive After Surgery","Preserving Brain Health After Surgery: Does Light General Anesthesia Reduce Postoperative Delirium and Cognitive Decline Compared With Deep General Anesthesia in Older Adults?","Balanced-2","Inclusion Criteria:\n\n* Patients aged ≥ 65 years, and Māori, Pacific or Indigenous participants aged ≥ 55 years who are undergoing major elective or non-elective surgery with expected surgical duration ≥ 2 hours and postoperative hospital stay ≥ 2 nights.\n* Having general anesthesia using total intravenous anesthesia (TIVA) with pEEG monitoring\n* Able to provide informed consent (including patients with mild preoperative neurocognitive disorders)\n\nExclusion Criteria:\n\n* Intracranial or cardiac surgery\n* Undergoing surgery with 'wake up' test\n* Previous enrollment in Balanced-2 study\n* Terminal illness with expected survival \\\u003C3 months\n* Emergency surgery within 6 hours of presentation to hospital\n* Cognitive impairment with no capacity to consent or activated enduring power of attorney\n* Clinically impaired and unable to consent due to acute pathology or preoperative delirium",{"count":214,"type":22},2766,[25],"The goal of this clinical trial (Balanced-2 study) is to compare light to deep general anesthesia using widely available brain monitors, to see if 'light' anesthesia could reduce rates of delirium, cognitive decline, and disability in older adults undergoing major surgery.\n\nDelirium is the most common serious surgical complication, occurring in an estimated one in four older adults undergoing major surgery. Delirium causes significant distress to patients and family, and is associated with prolonged hospital stay, physical disability, progression to dementia-like illnesses, and discharge to long-term care. Between 10 - 30% of adults aged 70 years and above have surgery every year, and preserving brain health and wellbeing is an important priority during this time.\n\nOlder adults (aged ≥65 years, or Indigenous, Pacific patients aged ≥55 years) undergoing major surgery with general anesthesia (excluding heart and brain surgery) and able to provide consent will be able to participate. Participants will be randomized to two groups - a lighter general anesthesia group and a deeper general anesthesia group using processed electroencephalography (a brain monitor that provides information on depth of anesthesia using brain waves). The anesthesiologist will titrate anesthetic drugs according to the brain monitor. Participants will be followed up to determine if they experience delirium after surgery, and longer term impact of delirium such as cognitive and physical decline will also be measured.\n\nIf found to be effect, this simple, cheap, and widely available treatment could reduce disability, preserve brain health and wellbeing of many older adults undergoing surgery worldwide, and save millions in healthcare dollars.",[218,219,220,46,182,221],"Delirium, Postoperative","Anesthesia","Surgery-Complications","Cognitive Decline",[223,224,225,226,227],"randomized controlled trial","multicentre","clinical trial","depth of anaesthesia","postoperative delirium","2025-09-22",{"date":230,"type":71},"2025-09-25",{"date":232,"type":71},"2024-05-20",{"date":234,"type":22},"2028-12-31",{"name":236,"class":237},"Auckland City Hospital","OTHER_GOV",3,{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":16,"sex":17,"minAge":87,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":257,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":79},"100432486","virtual-reality-glasses-use-to-improve-lateropulsion-and-the-post-stroke-postural-vertical-100432486","NCT04911738","VIrtual Reality Glasses Use to Improve Lateropulsion and the Post-stroke Postural Vertical","VIrtual Reality Glasses Use to Improve Lateropulsion and the Post-stroke Postural Vertical (VIRGIL)","VIRGIL","Inclusion Criteria:\n\n* 20 stroke participants\n\n  * Hospitalized in neurorehabilitation\n  * Hemisphere stroke (Right or left)\n  * Stroke delay \\\u003C 6 months\n  * Presence of lateropulsion assessed by the Scale for Contraversive Pushing (SCP) \\> 0.5\n* 20 healthy participants\n\n  * No history of stroke or others neurological pathologies\n  * No balance disorders\n  * No history of vestibular or dizzissness disorders\n\nExclusion Criteria:\n\n* All\n\n  * History of psychiatric disorders\n  * Nyctophobia\n  * Advanced heart failure\n  * Severe trunk deformation with C7 lateral \\> 30 mm due to a independant cause beyond the stroke (i.e., scoliosis) or history of postural disorder\n* 20 Stroke participants\n\n  * Medical instability making the assessment impossible\n  * Comprehension deficits with Boston Diagnostic Aphasia Examination gravity score ≥3\n  * History of vestibular or dizzissness disorders\n  * No previous neurological history interfering with balance\n  * Inability to understand and execute simple orders\n  * Severe untreated depression (Aphasic Depression Rating Scale (ADRS) score \\>15)","80 Years",{"count":249,"type":22},40,[25],"VIRGIL is a monocentric interventional study aiming to investigate the effect of immersion in a virtual tilted room on modulation of the verticality representation (postural vertical \\[PV\\] and visual vertical \\[VV\\]), which in turn might affect body orientation (head and trunk). To this end, the investigators will conduct a within-person randomized trial including post-stroke patients and healthy participants.",[253,254,255,256,46],"Stroke","Brain Diseases","Cerebrovascular Disorders","Postural; Defect",[258,259,260,261],"Lateropulsion","Verticality representation","Virtual reality","Rehabilitation","2025-05-16",{"date":264,"type":71},"2025-05-21",{"date":266,"type":71},"2021-06-15",{"date":268,"type":22},"2026-05-30",{"name":270,"class":78},"University Hospital, Grenoble",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":279,"conditions":280,"keywords":284,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":79},"100061146","human-epilepsy-genetics--neuronal-migration-disorders-study-100061146","NCT00041600","Human Epilepsy Genetics--Neuronal Migration Disorders Study","INCLUSION:\n\n* Males and females of any age.\n* Persons with a brain malformation or disorder of cognition (familial intellectual disability \\[previously known as mental retardation\\] or autism).\n\nEXCLUSION:\n\n* Persons without a brain malformation or disorder of cognition (familial intellectual disability (previously known as mental retardation\\] or autism).",{"count":278,"type":22},3500,"The purpose of this study is to identify genes responsible for epilepsy, brain malformations and disorders of human cognition.",[281,282,46,283],"Brain Malformation","Neuronal Migration Disorder","Epilepsy",[285,286,287,288,289,290,291,292,293,294,295],"epilepsy","seizures","disorders of human cognition","neuronal migration","neuronal migration disorders","lissencephaly","schizencephaly","polymicrogyria","heterotopia","microcephaly","pachygyria","2023-09-20",{"date":298,"type":71},"2023-09-21",{"date":300,"type":4},"1996-04",{"date":302,"type":22},"2030-06",{"name":304,"class":78},"Harvard University Faculty of Medicine",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":16,"sex":17,"minAge":175,"maxAge":247,"enrollmentInfo":312,"targetDuration":4,"studyType":23,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":79},"100507340","a-multi-domain-lifestyle-intervention-among-aged-community-residents-in-zhejiang-china-100507340","NCT05886114","A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China","HERITAGE","Inclusion Criteria:\n\n* At risk of cognitive decline: cognitive performance at the mean level or slightly lower than expected for age with no dementia (AD8\\>=3 and\u002For 5-min MoCA \\>, \\\u003C 11)\n* Free of physical disabilities that preclude participation in the study\n* Willing to complete all study-related activities for 24 months\n* Willing to be randomized to either lifestyle intervention group\n\nExclusion Criteria:\n\n* Diagnosed dementia patients\n* Diagnosed major depression or other neuropsychological diseases\n* Malignant diseases\n* Symptomatic cardiovascular disease\n* Revascularization within one year\n* Severe loss of vision, hearing or communicative ability",{"count":313,"type":22},1200,[25],"A study conducted in Finland discovered that a multidomain intervention, consisting of physical activity, nutritional guidance, cognitive training, social activities, and management of vascular risk factors, effectively decelerated cognitive decline in healthy older adults who were at an increased risk of cognitive decline. The HERITAGE study is a 2-year clustered randomized controlled trial (clustered-RCT) that explores the efficacy of a multidomain intervention among 1200 elderly residents with a higher risk of cognitive decline and dementia in Zhejiang Province, China",[149,93,317,318,254,319,187,150,320,46],"Vascular Cognitive Impairment","Dement","Central Nervous System Diseases","Mental Disorder","2023-06-04",{"date":323,"type":71},"2023-06-06",{"date":325,"type":22},"2023-05-28",{"date":327,"type":22},"2027-04-28",{"name":329,"class":78},"Zhejiang University"]